Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT plus fruquintinib and sintilimab in advanced MSS/pMMR colorectal cancer
ChiCTR2600134952Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic fecal microbiota, fruquintinib and sintilimab in colorectal cancer (CRC) and colorectal adenocarcinoma (2 arms), sponsored by The First Hospital of Hebei Medical University. Primary endpoint: Progression-Free Survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiotafruquintinibsintilimab
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600134952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134952.